PET-CT in Idiopathic Pulmonary Fibrosis
Research type
Research Study
Full title
PET-CT in Idiopathic Pulmonary Fibrosis.
IRAS ID
174158
Contact name
Simon Hart
Contact email
Sponsor organisation
Hull and East Yorkshire Hospitals NHS Trust
Duration of Study in the UK
1 years, 3 months, 31 days
Research summary
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease associated with significant morbidity and early mortality. The disease course in IPF is heterogeneous with some patients having slow lung function decline with only minor symptoms and others having rapid lung function decline and disabling symptoms leading to death. Although clinical models are in development to aid prognostication these remain unproven in the general IPF population. There is a lack of biomarkers that can be used to monitor response to therapy, identify active disease and aid prognostication. The development of new imaging modalities that provide structural and functional information may address this. \n\nPositron emission tomography computerised tomography (PET-CT) combines conventional CT using x-rays and the radioisotope fluorodeoxyglucose (FDG) to provide structural information and identify metabolically active tissues. \n\nWe propose to compare single and dual time point analysis of 18FDG-PET-CT imaging at baseline in a well characterised UK population of patients with IPF, diagnosed by multidisciplinary consensus according to the 2011 international guidelines. Associations with lung function measurements, indices of exercise capacity and symptom scores over 12 months will provide preliminary data about the relationship between lung 18FDG uptake on PET-CT and IPF disease progression. A further PET-CT will be undertaken in a subgroup of patients at 1 year to improve our understanding of the merits of serial PET-CT imaging. \n
REC name
North West - Preston Research Ethics Committee
REC reference
15/NW/0911
Date of REC Opinion
23 Dec 2015
REC opinion
Further Information Favourable Opinion